Profile data is unavailable for this security.
About the company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
- Revenue in USD (TTM)27.08m
- Net income in USD-37.00m
- Incorporated2012
- Employees91.00
- LocationAclaris Therapeutics Inc701 Lee Road, Suite 103WAYNE 19087United StatesUSA
- Phone+1 (484) 324-7933
- Fax+1 (302) 655-5049
- Websitehttps://www.aclaristx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actuate Therapeutics Inc | -100.00bn | -100.00bn | 175.20m | 11.00 | -- | -- | -- | -- | -- | -- | -- | -1.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -22.74 | -- | -- | -- |
Cardiff Oncology Inc | 689.00k | -43.01m | 176.92m | 31.00 | -- | 3.41 | -- | 256.78 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 178.26m | 75.00 | -- | 2.61 | -- | 28.82 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Galectin Therapeutics Inc | 0.00 | -48.03m | 179.98m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.90m | 180.82m | 18.00 | -- | 3.38 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Greenwich Lifesciences Inc | 0.00 | -10.22m | 184.81m | 3.00 | -- | 31.27 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
Aclaris Therapeutics Inc | 27.08m | -37.00m | 187.86m | 91.00 | -- | 1.44 | -- | 6.94 | -0.5198 | -0.5198 | 0.3806 | 1.82 | 0.1352 | -- | 78.61 | 297,582.40 | -18.47 | -47.29 | -20.87 | -53.87 | 53.53 | 44.00 | -136.65 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Sagimet Biosciences Inc | 2.00m | -29.25m | 188.34m | 10.00 | -- | 1.02 | -- | 94.17 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Inhibikase Therapeutics Inc | 79.57k | -18.38m | 188.77m | 8.00 | -- | 4.06 | -- | 2,372.40 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Black Diamond Therapeutics Inc | 0.00 | -73.10m | 191.26m | 54.00 | -- | 1.96 | -- | -- | -1.36 | -1.36 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -47.12 | -40.29 | -53.28 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 193.46m | 51.00 | -- | 0.793 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
Gossamer Bio Inc | 105.32m | -71.65m | 194.15m | 135.00 | -- | 3.59 | -- | 1.84 | -0.3283 | -0.3283 | 0.4595 | 0.2389 | 0.3014 | -- | -- | 780,162.90 | -20.51 | -57.43 | -23.67 | -64.38 | -- | -- | -68.03 | -- | -- | -6.84 | 0.7847 | -- | -- | -- | 21.61 | -- | -- | -- |
Verastem Inc | 10.00m | -93.45m | 198.50m | 73.00 | -- | 16.24 | -- | 19.85 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -117.23m | 203.60m | 140.00 | -- | 1.81 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Atossa Therapeutics Inc | 0.00 | -25.91m | 203.73m | 10.00 | -- | 2.54 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Holder | Shares | % Held |
---|---|---|
BML Capital Management LLCas of 30 Sep 2024 | 14.25m | 19.97% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 4.67m | 6.54% |
D. E. Shaw & Co. LPas of 30 Jun 2024 | 3.32m | 4.65% |
Millennium Management LLCas of 30 Sep 2024 | 3.01m | 4.21% |
Rock Springs Capital Management LPas of 30 Jun 2024 | 2.75m | 3.86% |
Stonepine Capital Management LLCas of 30 Jun 2024 | 1.93m | 2.70% |
Acadian Asset Management LLCas of 30 Jun 2024 | 1.91m | 2.68% |
Trium Capital LLPas of 30 Sep 2024 | 1.91m | 2.68% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 1.91m | 2.68% |
Two Sigma Advisers LPas of 30 Jun 2024 | 1.44m | 2.01% |